Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Taiping Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-1689-6908; OpenAlex author ID A5101664916. Sources: OpenAlex.

Their work

Papers
113 (first author 8, last author 28)
Trials
0
Grants
0
Labs led
1
Collaborators
168
Papers, trials and grants by year

2011: 2 papers · 2012: 4 papers · 2013: 6 papers · 2014: 8 papers · 2015: 5 papers · 2016: 7 papers · 2017: 5 papers · 2018: 9 papers · 2019: 9 papers · 2020: 10 papers · 2021: 16 papers · 2022: 6 papers · 2023: 10 papers · 2024: 9 papers · 2025: 5 papers · 2026: 2 papers

Papers 50 of 113

  1. Integrated scRNA-Seq and functional profiling reveal CD52 as a driver of pancreatic ductal adenocarcinoma metastasis and immunosuppression. Last author DOI 10.1038/s41389-026-00637-x↗
  2. Nab-paclitaxel plus S-1 induction chemotherapy for patients with locally advanced pancreatic cancer: a multicenter, open-label phase 2 study. Co-author DOI 10.1038/s41392-026-02741-1↗
  3. SPP1+ Venous Endothelial Cells and CRABP2+ Tumor Cells Contribute to Favorable Body and Tail Pancreatic Ductal Adenocarcinoma Tumor Microenvironment. Co-author DOI 10.1002/mc.23936↗
  4. Decipher the single-cell level responses to chemotherapy in pancreatic ductal adenocarcinoma by a cross-time context graph model. Co-author DOI 10.1016/j.canlet.2025.217751↗
  5. Polyamines in pancreatic cancer: reshaping the immunosuppressive tumor microenvironment. Last author DOI 10.1016/j.canlet.2025.218016↗
  6. RNA binding protein DDX3X drives pancreatic cancer progression via the TLE2-MYL9 axis. Co-author DOI 10.1126/sciadv.adw9519↗
  7. Feasibility of simplified Patlak parametric imaging with scaled population-based input function on pancreatic cancer. Co-author DOI 10.1186/s40658-025-00758-z↗
  8. The new era of pancreatic cancer treatment: Application of nanotechnology breaking through bottlenecks. First author DOI 10.1016/j.canlet.2024.216979↗
  9. E3 ubiquitin ligase RBCK1 confers ferroptosis resistance in pancreatic cancer by facilitating MFN2 degradation. Last author DOI 10.1016/j.freeradbiomed.2024.05.031↗
  10. The NF-κB/NUAK2 signaling axis regulates pancreatic cancer progression by targeting SMAD2/3. Last author DOI 10.1016/j.isci.2024.109406↗
  11. Multiomics integration reveals NETosis heterogeneity and TLR2 as a prognostic biomarker in pancreatic cancer. Co-author DOI 10.1038/s41698-024-00586-x↗
  12. Pancreatic ductal adenocarcinoma chemoresistance: From metabolism reprogramming to novel treatment. Last author DOI 10.1097/cm9.0000000000002758↗
  13. FBXO32 Stimulates Protein Synthesis to Drive Pancreatic Cancer Progression and Metastasis. Last author DOI 10.1158/0008-5472.can-23-3638↗
  14. Unbiasedly decoding the tumor microenvironment with single-cell multiomics analysis in pancreatic cancer. Co-author DOI 10.1186/s12943-024-02050-7↗
  15. CALB2 drives pancreatic cancer metastasis through inflammatory reprogramming of the tumor microenvironment. Co-author DOI 10.1186/s13046-024-03201-w↗
  16. Human Equilibrative Nucleoside Transporter 1: Novel Biomarker and Prognostic Indicator for Patients with Gemcitabine-Treated Pancreatic Cancer. Last author DOI 10.2147/cmar.s465098↗
  17. Prognostic value of preoperative [68 Ga]Ga-FAPI-04 PET/CT in patients with resectable pancreatic ductal adenocarcinoma in correlation with immunohistological c… Co-author DOI 10.1007/s00259-022-06100-4↗
  18. Comparing the clinical value of baseline [68 Ga]Ga-FAPI-04 PET/CT and [18F]F-FDG PET/CT in pancreatic ductal adenocarcinoma: additional prognostic value of the… Co-author DOI 10.1007/s00259-023-06297-y↗
  19. Genomic analysis and filtration of novel prognostic biomarkers based on metabolic and immune subtypes in pancreatic cancer. Co-author DOI 10.1007/s13402-023-00836-3↗
  20. mTOR inhibitor, gemcitabine and PD-L1 antibody blockade combination therapy suppresses pancreatic cancer progression via metabolic reprogramming and immune mic… Last author DOI 10.1016/j.canlet.2022.216020↗
  21. Cancer-associated fibroblasts: A key target to snatch victory from defeat in therapy resistance associated with the pancreatic cancer stroma. First author DOI 10.1016/j.canlet.2023.216279↗
  22. Novel strategies optimize immunotherapy by improving the cytotoxic function of T cells for pancreatic cancer treatment. Last author DOI 10.1016/j.canlet.2023.216423↗
  23. PRKRA promotes pancreatic cancer progression by upregulating MMP1 transcription via the NF-κB pathway. Last author DOI 10.1016/j.heliyon.2023.e17194↗
  24. Regulatory role of RNA modifications in the treatment of pancreatic ductal adenocarcinoma (PDAC). Last author DOI 10.1016/j.heliyon.2023.e20969↗
  25. Using a microRNA panel of circulating exosomes for diagnosis of pancreatic cancer: multicentre case-control study. Last author DOI 10.1093/bjs/znac375↗
  26. Epidemiology of pancreatic cancer: New version, new vision. Last author DOI 10.21147/j.issn.1000-9604.2023.05.03↗
  27. HIF-1α-regulated stanniocalcin-1 mediates gemcitabine resistance in pancreatic ductal adenocarcinoma via PI3K/AKT signaling pathway. Co-author DOI 10.1002/mc.23420↗
  28. Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of pancreatic cancer. Co-author DOI 10.1016/j.jncc.2022.08.006↗
  29. Comparison of adjuvant gemcitabine plus S-1 with S-1 monotherapy for pancreatic ductal adenocarcinoma: Retrospective real-world data. Co-author DOI 10.1016/j.neo.2022.100841↗
  30. Win or loss? Combination therapy does improve the oncolytic virus therapy to pancreatic cancer. Last author DOI 10.1186/s12935-022-02583-1↗
  31. Is neoadjuvant chemoradiotherapy for pancreatic cancer beneficial: A systematic review and meta-analysis. Last author DOI 10.3389/fonc.2022.979390↗
  32. Meta-analysis of robotic versus open pancreaticoduodenectomy in all patients and pancreatic cancer patients. Last author DOI 10.3389/fsurg.2022.989065↗
  33. Comparison of minimal invasive versus open radical antegrade modular pancreatosplenectomy (RAMPS) for pancreatic ductal adenocarcinoma: a single center retrosp… Co-author DOI 10.1007/s00464-020-07938-1↗
  34. Radical antegrade modular pancreatosplenectomy (RAMPS) versus conventional distal pancreatosplenectomy (CDPS) for left-sided pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00595-020-02203-3↗
  35. Metformin inhibits pancreatic cancer metastasis caused by SMAD4 deficiency and consequent HNF4G upregulation. First author DOI 10.1007/s13238-020-00760-4↗
  36. CREPT serves as a biomarker of poor survival in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s13402-020-00569-7↗
  37. Advances in the epidemiology of pancreatic cancer: Trends, risk factors, screening, and prognosis. Co-author DOI 10.1016/j.canlet.2021.06.027↗
  38. Do novel treatment strategies enhance T cell-mediated Immunity: Opportunities and challenges in pancreatic cancer immunotherapy. Last author DOI 10.1016/j.intimp.2020.107199↗
  39. Integrative Genomic Analysis of Gemcitabine Resistance in Pancreatic Cancer by Patient-derived Xenograft Models. Co-author DOI 10.1158/1078-0432.ccr-19-3975↗
  40. Targeting hypoxic tumor microenvironment in pancreatic cancer. Co-author DOI 10.1186/s13045-020-01030-w↗
  41. High-resolution Hi-C maps highlight multiscale 3D epigenome reprogramming during pancreatic cancer metastasis. Co-author DOI 10.1186/s13045-021-01131-0↗
  42. Preclinical models of pancreatic ductal adenocarcinoma: challenges and opportunities in the era of precision medicine. Last author DOI 10.1186/s13046-020-01787-5↗
  43. Correction to: MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-021-02152-w↗
  44. Novel therapies targeting hypoxia mechanism to treat pancreatic cancer. Last author DOI 10.21147/j.issn.1000-9604.2021.02.09↗
  45. Identification and Validation of Constructing the Prognostic Model With Four DNA Methylation-Driven Genes in Pancreatic Cancer. Co-author DOI 10.3389/fcell.2021.709669↗
  46. Comprehensive Analysis of Autophagy-Associated lncRNAs Reveal Potential Prognostic Prediction in Pancreatic Cancer. Co-author DOI 10.3389/fonc.2021.596573↗
  47. Suppression of the HBP Function Increases Pancreatic Cancer Cell Sensitivity to a Pan-RAS Inhibitor. Co-author DOI 10.3390/cells10020431↗
  48. The Role of Mitochondria in the Chemoresistance of Pancreatic Cancer Cells. Last author DOI 10.3390/cells10030497↗
  49. The enhancement of glycolysis regulates pancreatic cancer metastasis. Co-author DOI 10.1007/s00018-019-03278-z↗
  50. Combined blockade of TGf-β1 and GM-CSF improves chemotherapeutic effects for pancreatic cancer by modulating tumor microenvironment. Co-author DOI 10.1007/s00262-020-02542-7↗

Closest collaborators

The 25 strongest of 168 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Lei You · 59 shared papers, 2012–2025 · strength 5.52
  2. Wenhao Luo · 26 shared papers, 2019–2026 · strength 5.01
  3. Yupei Zhao · 47 shared papers, 2013–2026 · strength 4.72
  4. Gang Yang · 36 shared papers, 2017–2025 · strength 4.37
  5. Jiangdong Qiu · 21 shared papers, 2019–2025 · strength 3.46
  6. Yueze Liu · 22 shared papers, 2019–2025 · strength 3.24
  7. Jinxin Tao · 18 shared papers, 2020–2026 · strength 3.20
  8. Zhe Cao · 25 shared papers, 2014–2026 · strength 2.88
  9. Fangyu Zhao · 21 shared papers, 2018–2024 · strength 2.52
  10. Jiangdong Qiu · 17 shared papers, 2018–2026 · strength 2.36
  11. Mengyu Feng · 17 shared papers, 2017–2023 · strength 1.74
  12. Guangyu Chen · 12 shared papers, 2020–2025 · strength 1.71
  13. Hua Huang · 13 shared papers, 2014–2025 · strength 1.65
  14. Yu-Pei Zhao · 27 shared papers, 2011–2025 · strength 1.60
  15. Junchao Guo · 18 shared papers, 2013–2022 · strength 1.43
  16. Jianchun Xiao · 10 shared papers, 2013–2025 · strength 1.34
  17. Li Zhou · 23 shared papers, 2011–2020 · strength 1.32
  18. Ruobing Wang · 6 shared papers, 2023–2024 · strength 1.12
  19. Guangbing Xiong · 11 shared papers, 2016–2023 · strength 1.04
  20. Dan Su · 6 shared papers, 2022–2024 · strength 1.03
  21. Yifan Fu · 5 shared papers, 2024–2026 · strength 0.99
  22. Menghua Dai · 10 shared papers, 2013–2022 · strength 0.94
  23. Tao Liu · 4 shared papers, 2024–2025 · strength 0.74
  24. Hao Chen · 4 shared papers, 2019–2026 · strength 0.69
  25. Bo Ren · 4 shared papers, 2020–2025 · strength 0.67

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.